Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA271730 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Gene expression analysis of MEL-18-silenced MCF7 cell lines. MEL-18 is a component of the polycomb repressive complex (PRC)-1, which is a critical epigenetic modulator of stem cell regulation and normal and cancerous development. Accumulating studies have suggested that MEL-18 might act as a tumor suppressor in several human tumors, including breast cancer. Results provide insight into the functional role of MEL-18 in estrogen-dependent breast cancer.
2015-05-01 | GSE64716 | GEO
Project description:Gene expression profile in MCF7 breast cancer cells after siRNA knock down of estrogen receptor alpha (ESR1)
2025-01-24 | E-GEOD-37820 | ExpressionAtlas
Project description:Gene expression analysis of MEL-18-silenced MCF7 cell lines. MEL-18 is a component of the polycomb repressive complex (PRC)-1, which is a critical epigenetic modulator of stem cell regulation and normal and cancerous development. Accumulating studies have suggested that MEL-18 might act as a tumor suppressor in several human tumors, including breast cancer. Results provide insight into the functional role of MEL-18 in estrogen-dependent breast cancer. MCF7 cells stably infected with lentiviruses encoding either control (shCon) or MEL-18 shRNA (shMEL) were cultured in phenol-red free DMEM supplemented with 10% FBS for 48 h. Total RNA was isolated from the cultures using Trizol reagent. For each of the 2 conditions, 2 biological replicates were included. In total, 4 microarray samples were analyzed; 2 controls and 2 shRNA MEL-18 knockdowns. All labeling, hybridization and scanning steps were performed according to the manufacturers’ instructions.
2015-05-01 | E-GEOD-64716 | biostudies-arrayexpress
Project description:Gene expression analysis on MEL-18-knockdown BT474 cells. MEL-18, a polycomb group protein and a member of the polycomb repressive complex 1 (PRC1), have suggested as a tumor suppressor in several cancer, including breast cancer. The results provides that the depletion of MEL-18 in HER2-positive breast cancer causes the activation of ErbB signaling pathway. We proposed that MEL-18 is a novel prognostic and therapeutic marker for HER2-positive breast cancer.
2018-07-31 | GSE92504 | GEO
Project description:Transcription profiling by array of MCF7 breast cancer cells after treatment with doxorubicin
2025-01-24 | E-GEOD-39870 | ExpressionAtlas
Project description:Resveratrol induces downregulation of DNA repair genes in MCF7 human breast cancer cells.
2025-01-24 | E-GEOD-25412 | ExpressionAtlas
Project description:Networking of differentially expressed genes in human MCF7 breast cancer cells resistant to methotrexate
2025-01-24 | E-GEOD-16070 | ExpressionAtlas
Project description:Gene expression underlying estrogen receptor activation versus inhibition in breast cancer cells
2025-01-24 | E-GEOD-35031 | ExpressionAtlas
Project description:Transcription profiling by array time series of human MCF7 breast cancer cells treated with estradiol
2025-01-16 | E-GEOD-11352 | ExpressionAtlas
Project description:RNA-sequencing analysis of MEL-18 WT- or MEL-18 T334A-overexpressing MDA-MB-231 cell lines. MEL-18, a core component of polycomb-repressive complex (PRC)-1, has been known to be phosphorylated at multiple residues in vitro; however, its functional roles in mammalian cells and human cancer remains largely unknown. Here, we examined the effect of MEL-18 phosphorylation at T334 site on polycomb-mediated epigenetic silencing in human breast cancer. Our results demonstrated that the phosphorylation of MEL-18 at T334 alters its genomic distribution and transcriptional activity that reflects functional change of MEL-18 in modulating breast tumour progression.
2022-03-01 | GSE115591 | GEO